PAM481

Gefapixant en tos crónica

MEDICAMENTOS EN ESPAÑA

Valoración Gefapixant

▼LYFNUA® (MSD)

INNOVACIÓN MODERADA (**)

Grupo Terapéutico (ATC) : R05DB29. SUPRESORES DE LA TOS, EXCLUYENDO COMBINACIONES CON EXPECTORANTES. OTROS SUPRESORES DE LA TOS.

Aporta algunas mejoras, pero no implica cambios sustanciales en la terapéutica estándar.

Indicaciones autorizadas : tratamiento de la tos crónica refractaria o idiopática.

Bibliografía

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ficha técnica de Lyfnua® (gefapixant). 2024. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/1211613002/ FT_1211613002.html.pdf. Birring SS, Dicpinigaitis P, Morice A, Smith JA, McGarvey L, Pavord I et al. Patient-reported improvements with gefapixant, a P2X3-receptor antagonist, over 52 weeks in two phase 3 clinical trials for refractory or unexplained chronic cough. Thorax. 2021; 76(Suppl 2): A99. Chung KF, Mazzone SB. Cough. In: Broadus WC, Ernst JD, Lazarus SC, Nadel JA, Gotway MB. Murray and Nadel’s Textbook of Respiratory Medicine. 2016; 30: 497-514.e5. Cortijo Gimeno J, Milara Paya J, Morcillo Sánchez E. Expectorantes, antitusivos y mucolíticos. En: Trastornos respiratorios, genitourinarios, dermatológicos, oftalmológicos y otológicos. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos. 2021; 77-104. European Medicines Agency (EMA). Lyfnua®. European Public Assessment Report (EPAR). 2023. EMA/357321/2023 Corr.1. Disponible en: https://www.ema.europa.eu/en/documents/ assessment-report/lyfnua-epar-public-assessment-report_en.pdf. Jacobson KA, IJzerman AP, Müller CE. Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets. Biochem Pharmacol. 2021; 187: 114311. DOI: 10.1016/j. bcp.2020.114311.

McGarvey L, Sher M, Shvarts YG, Lu S, Wu W-C, Xu P et al. The efficacy and safety of gefapixant in a phase 3b trial of patients with recent-onset chronic cough. Lung. 2023; 201(2): 111-8. McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J et al. COUGH-1 and COUGH-2 Investigators. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel group, placebo-controlled, phase 3 trials. Lancet. 2022; 399(10328): 909-923. DOI: 10.1016/S0140-6736(21)02348-5. Parker SM, Smith JA, Birring SS, Chamberlain-Mitchell S, Gruffydd-Jones K, Haines J et al. British Thoracic Society Clinical Statement on chronic cough in adults. Thorax. 2023; 78: s3-s19. Weinberger SE, Saukkonen K. Evaluation and treatment of subacute and chronic cough in adults. UpToDate. 2023. Disponible en: https://www.uptodate.com/contents/evaluation-and-treatment of-subacute-and-chronic-cough-in-adults (acceso a 13 de febrero de 2025). Zheng Z, Huang J, Xiang Z, Wu T, Lan X, Xie S et al. Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis. EClinicalMedicine. 2023; 62(102100): 102100. DOI: 10.1016/j. eclinm.2023.102100

201